China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc.
See more information about China Pharma Holdings, Inc.
China Pharma Holdings, Inc. approved for Amex listing
China Pharma (OTC:CPHI) yesterday received approval to list its securities on NYSE Amex. It expects to start trading on the exchange today.
In connection with its listing on NYSE Amex, the Company's ticker symbol will change to "CPHI" from "CPHI.OB."
Ms. Zhilin Li, CEO and President of China Pharma, commented, "It is a major milestone to move to NYSE Amex, and we are proud of our fulfillment of this target. We believe that NYSE Amex provides excellent exposure for companies from emerging markets, such as ours."
